Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Denardo

Showing results (261-270 of 274) with videos related to

Pageof 28
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RITSally J DeNardo, Gerald L DeNardo, A Yuan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 1999
Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin AC M Richman, S J DeNardo, R T O'Donnell, et al.
International Journal of Oncology|September 6, 2007
Characteristics of dimeric (bis) bidentate selective high affinity ligands as HLA-DR10 beta antibody mimics targeting non-Hodgkin's lymphomaGerald L DeNardo, Saphon Hok, Arutselvan Van Natarajan, et al.
Cancer Biotherapy & Radiopharmaceuticals|March 31, 2000
Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapyS J DeNardo, P A Burke, B R Leigh, et al.
Anticancer Research|May 1, 1997
Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibodyS J Denardo, L F O'Grady, C M Richman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2007
Selective high-affinity ligand antibody mimics for cancer diagnosis and therapy: initial application to lymphoma/leukemiaRod Balhorn, Saphon Hok, Patricia A Burke, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 20, 1999
67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphomaS J DeNardo, G L DeNardo, D L Kukis, et al.
Cancer Biology & Therapy|June 7, 2008
Pre-clinical evaluation and efficacy studies of a melanin-binding IgM antibody labeled with 188Re against experimental human metastatic melanoma in nude miceEkaterina Dadachova, E Revskaya, M A Sesay, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 13, 2000
Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibodyG L DeNardo, S J DeNardo, K R Lamborn, et al.
Radiation Protection Dosimetry|April 11, 2006
MINERVA: a multi-modality plugin-based radiation therapy treatment planning systemC A Wemple, D E Wessol, D W Nigg, et al.
Pageof 28

Showing results (261-270 of 274) with videos related to

Sort By:
Pageof 28
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RITSally J DeNardo, Gerald L DeNardo, A Yuan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 1999
Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin AC M Richman, S J DeNardo, R T O'Donnell, et al.
International Journal of Oncology|September 6, 2007
Characteristics of dimeric (bis) bidentate selective high affinity ligands as HLA-DR10 beta antibody mimics targeting non-Hodgkin's lymphomaGerald L DeNardo, Saphon Hok, Arutselvan Van Natarajan, et al.
Cancer Biotherapy & Radiopharmaceuticals|March 31, 2000
Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapyS J DeNardo, P A Burke, B R Leigh, et al.
Anticancer Research|May 1, 1997
Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibodyS J Denardo, L F O'Grady, C M Richman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2007
Selective high-affinity ligand antibody mimics for cancer diagnosis and therapy: initial application to lymphoma/leukemiaRod Balhorn, Saphon Hok, Patricia A Burke, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 20, 1999
67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphomaS J DeNardo, G L DeNardo, D L Kukis, et al.
Cancer Biology & Therapy|June 7, 2008
Pre-clinical evaluation and efficacy studies of a melanin-binding IgM antibody labeled with 188Re against experimental human metastatic melanoma in nude miceEkaterina Dadachova, E Revskaya, M A Sesay, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 13, 2000
Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibodyG L DeNardo, S J DeNardo, K R Lamborn, et al.
Radiation Protection Dosimetry|April 11, 2006
MINERVA: a multi-modality plugin-based radiation therapy treatment planning systemC A Wemple, D E Wessol, D W Nigg, et al.
Pageof 28